| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9328416 | Gynecologic Oncology | 2005 | 7 Pages |
Abstract
While most gynecologic oncologists in our survey recommend adjuvant therapy for stage IIIA endometrial carcinoma, our results showed that patients with malignant cytology only would receive different treatments than patients with adenxal or serosal involvement. Histology and grade of the tumor are predictors of therapy recommendations over malignant cytology. Most respondents agreed that patients with malignant cytology should remain in stage IIIA.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Christine M. Lee, Brian M. Slomovitz, Marilyn Greer, Sheena Sharma, Mary Ann Gregurich, Thomas Burke, Karen H. Lu, Lois M. Ramondetta,